Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin alpha-4 (ITGA4), also known as CD49d, is a member of the integrin alpha chain family. It forms heterodimers with either beta 1 (α4β1/VLA-4) or beta 7 (α4β7) and plays key roles in cell adhesion and migration by mediating interactions between cells and extracellular matrix proteins. It is involved in immune cell trafficking and is a therapeutic target for inflammatory diseases.
Integrin α₄ antagonists block the interaction of integrin α₄ with its ligands (VCAM-1, MADCAM-1, fibronectin), thereby inhibiting cell adhesion and migration.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha-4 (CD49d).